Please login to the form below

Not currently logged in
Email:
Password:

study

This page shows the latest study news and features for those working in and with pharma, biotech and healthcare.

Gilead says switching studies back new HIV therapy Biktarvy

Gilead says switching studies back new HIV therapy Biktarvy

Gilead says switching studies back new HIV therapy Biktarvy. Patients who switched from rival Triumeq could maintain viral suppression over the trial period. ... The results of Study 1844 showed that patients who transferred to treatment with Biktarvy

Latest news

  • Gilead study resurrects HIV eradication hope Gilead study resurrects HIV eradication hope

    Gilead study resurrects HIV eradication hope. Intends to start human trials of its improved bNAb candidate. ... A preclinical study in non-human primates has suggested that it took months for virus levels to rebound after the pairing of oral toll-like

  • Another Alzheimer's bust as Merck & Co stops verubecestat study Another Alzheimer's bust as Merck & Co stops verubecestat study

    Another Alzheimer's bust as Merck &Co stops verubecestat study. Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai. ... The APECS study of verubecestat (MK-8931) has been terminated one the advice of the trial’s data

  • Shire says all its studies will publish in open access journals Shire says all its studies will publish in open access journals

    A 2016 study found that around half of all trials run by pharma companies, universities and other major research sponsors remained unpublished on the registry, but concluded that Shire had a ... The new policy means studies supported by the rare disease

  • Merck chalks up another win for Keytruda in lung cancer Merck chalks up another win for Keytruda in lung cancer

    Moreover, the drug hit its objective around a year earlier than expected - Merck was not due to report survival data from the study until early 2019. ... s recently-reported Impower150 study of PD-L1 inhibitor Tecentriq (atezolizumab) plus Avastin

  • Apple launches Watch-powered atrial fibrillation study Apple launches Watch-powered atrial fibrillation study

    Apple launches Watch-powered atrial fibrillation study. The firm's Apple Heart Study app will see it collaborate with Stanford Medicine. ... consultation with a study doctor and an electrocardiogram (ECG) patch for additional monitoring.

More from news
Approximately 5 fully matching, plus 1,194 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 6 fully matching, plus 305 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 53 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 27 fully matching, plus 348 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics